GeoVax Advances Gedeptin Toward Phase 2 and Partnership Opportunities

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced near-term milestones and strategic priorities for its oncology program, Gedeptin®, as it prepares for Phase 2 clinical initiation and potential partnership opportunities. The company is focusing on integrating Gedeptin into combination regimens, particularly with immune checkpoint inhibitors (ICIs), to align with evolving oncology treatment landscapes. GeoVax is targeting a Phase 2 trial in 2027 for first-line neoadjuvant treatment in resectable locally advanced head and neck cancer, evaluating tumor response, biomarker-driven immune activation, and event-free survival. Additionally, the company is expanding preclinical work across other solid tumors to identify optimal combination settings.

GeoVax is actively pursuing strategic collaborations, including clinical development partnerships and licensing arrangements. The company's foundation includes completed Phase 1/2 clinical experience, an Advisory Board, and expanded intellectual property for combination use with checkpoint inhibitors. Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) that converts a prodrug into a cytotoxic agent within the tumor microenvironment. GeoVax also advances GEO-MVA for mpox/smallpox and GEO-CM04S1 for COVID-19. For more details, visit www.geovax.com. The original release can be found on NEWMEDIAWIRE.

Chairman and CEO David A. Dodd emphasized the importance of clinical execution and advancing partnership discussions, stating, 'As combination therapy becomes more common across oncology, we believe Gedeptin is well positioned to be integrated into these regimens and contribute to improved treatment outcomes.' This strategic shift underscores GeoVax's commitment to addressing the growing need for effective combination immunotherapies in cancer treatment.